Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

By sjmartinez • August 31, 2023

Chew KW, Moser C, Yeh E, Wohl DA, Daar ES, Ritz J, Javan AC, Eron JJ, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S83-S91. doi: 10.1093/infdis/jiad300. PMID: 37650237; PMCID: PMC10469584.

Tags: ACTIV-2, covid-19, Harbor UCLA, Infectious Diseases, internal validity, patient-reported outcomes, Publications, symptom diary, time to symptom resolution

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Punnanithinont N, Kambalapalli S, Iskander B, Ichikawa K, Krishnan S, Lakshmanan S, Roy SK, Budoff M. "Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]